KalVista Pharmaceuticals (NASDAQ:KALV) Given "Buy" Rating at Jones Trading

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report)'s stock had its "buy" rating reiterated by analysts at Jones Trading in a report issued on Wednesday,Benzinga reports. They currently have a $30.00 price objective on the specialty pharmaceutical company's stock. Jones Trading's price objective would indicate a potential upside of 151.47% from the company's previous close.

A number of other equities analysts have also weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price objective for the company. Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a "buy" rating and a $22.00 target price on the stock. Citizens Jmp upgraded KalVista Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 31st. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $24.83.

Remove Ads

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV traded down $0.41 during trading on Wednesday, reaching $11.93. The company's stock had a trading volume of 275,700 shares, compared to its average volume of 386,462. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $15.50. The firm has a market cap of $593.11 million, a price-to-earnings ratio of -3.28 and a beta of 0.76. The firm has a 50 day moving average of $10.56 and a 200-day moving average of $10.25.

Insider Buying and Selling

In other news, major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of the company's stock in a transaction on Monday, February 3rd. The stock was purchased at an average price of $9.22 per share, with a total value of $134,261.64. Following the completion of the purchase, the insider now directly owns 5,012,796 shares in the company, valued at approximately $46,217,979.12. This trade represents a 0.29 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul K. Audhya sold 3,125 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the transaction, the insider now owns 100,334 shares in the company, valued at $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently made changes to their positions in KALV. Aquatic Capital Management LLC purchased a new stake in KalVista Pharmaceuticals during the fourth quarter valued at about $44,000. Tower Research Capital LLC TRC grew its position in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 5,502 shares during the last quarter. Legal & General Group Plc increased its stake in KalVista Pharmaceuticals by 22.5% in the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock worth $69,000 after purchasing an additional 1,494 shares during the period. Martin Worley Group bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock valued at $87,000 after purchasing an additional 2,043 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).